327 related articles for article (PubMed ID: 26616639)
21. Peritoneal kinetics of cancer antigen 125 in peritoneal dialysis patients: the relationship with peritoneal outcome.
Jiménez C; Díaz C; Selgas R; Auxiliadora Bajo M; del Peso G; Sánchez-Tomero JA; Gonzalez-Gancedo P
Adv Perit Dial; 1999; 15():36-9. PubMed ID: 10682069
[TBL] [Abstract][Full Text] [Related]
22. The clinical usefulness of peritoneal dialysis fluids with neutral pH and low glucose degradation product concentration: an open randomized prospective trial.
Choi HY; Kim DK; Lee TH; Moon SJ; Han SH; Lee JE; Kim BS; Park HC; Choi KH; Ha SK; Han DS; Lee HY
Perit Dial Int; 2008; 28(2):174-82. PubMed ID: 18332454
[TBL] [Abstract][Full Text] [Related]
23. Dialysate CA125 levels in stable peritoneal dialysis patients.
Okada T; Nakao T; Matsumoto H
Clin Nephrol; 1999 Jan; 51(1):65-6. PubMed ID: 9988153
[No Abstract] [Full Text] [Related]
24. Comparison of sodium removal in peritoneal dialysis patients treated by continuous ambulatory and automated peritoneal dialysis.
Maharjan SRS; Davenport A
J Nephrol; 2019 Dec; 32(6):1011-1019. PubMed ID: 31502219
[TBL] [Abstract][Full Text] [Related]
25. Influence of pH-neutral peritoneal dialysis solution.
Moriishi M; Kawanishi H; Kawai T; Takahashi S; Hirai T; Shishida M; Watanabe H; Takahashi N
Adv Perit Dial; 2002; 18():68-71. PubMed ID: 12402590
[TBL] [Abstract][Full Text] [Related]
26. Determinants of peritoneal solute transport rates in newly started nondiabetic peritoneal dialysis patients.
van Esch S; Zweers MM; Jansen MA; de Waart DR; van Manen JG; Krediet RT
Perit Dial Int; 2004; 24(6):554-61. PubMed ID: 15559485
[TBL] [Abstract][Full Text] [Related]
27. Necessity of correcting cancer antigen 125 appearance rates by body surface area.
Kawanishi H; Moriishi M; Harada Y; Sakikubo E; Nagai T; Tsuchiya S
Adv Perit Dial; 2000; 16():22-5. PubMed ID: 11045255
[TBL] [Abstract][Full Text] [Related]
28. Impact of combination therapy with peritoneal dialysis and hemodialysis on peritoneal function.
Moriishi M; Kawanishi H; Tsuchiya S
Adv Perit Dial; 2010; 26():67-70. PubMed ID: 21348383
[TBL] [Abstract][Full Text] [Related]
29. Impact of systemic and local peritoneal inflammation on peritoneal solute transport rate in new peritoneal dialysis patients: a 1-year prospective study.
Cho JH; Hur IK; Kim CD; Park SH; Ryu HM; Yook JM; Choi JY; Choi HJ; Choi HJ; Park JW; Do JY; Kim YL
Nephrol Dial Transplant; 2010 Jun; 25(6):1964-73. PubMed ID: 20100731
[TBL] [Abstract][Full Text] [Related]
30. Influence of dialysis duration, peritoneal transport parameters, and gender on effluent CA125 concentration in patients on peritoneal dialysis.
Mojahedi MJ; Hami M; Shakeri MT; Hekmat R
Iran J Kidney Dis; 2007 Oct; 1(2):78-81. PubMed ID: 19363281
[TBL] [Abstract][Full Text] [Related]
31. Do interleukin-6, hyaluronan, soluble intercellular adhesion molecule-1 and cancer antigen 125 in dialysate predict changes in peritoneal function? A 1-year follow-up study.
Martikainen T; Ekstrand A; Honkanen E; Teppo AM; Grönhagen-Riska C
Scand J Urol Nephrol; 2005; 39(5):410-6. PubMed ID: 16257844
[TBL] [Abstract][Full Text] [Related]
32. Intra-peritoneal interleukin-6 system is a potent determinant of the baseline peritoneal solute transport in incident peritoneal dialysis patients.
Oh KH; Jung JY; Yoon MO; Song A; Lee H; Ro H; Hwang YH; Kim DK; Margetts P; Ahn C
Nephrol Dial Transplant; 2010 May; 25(5):1639-46. PubMed ID: 20061317
[TBL] [Abstract][Full Text] [Related]
33. Pancreatic lipase activity in overnight effluent predicts high transport status in peritoneal dialysis patients.
Idei M; Tabe Y; Hamada C; Miyake K; Takemura H; Io H; Wakita M; Horii T; Tomino Y; Ohsaka A; Miida T
Clin Chim Acta; 2016 Nov; 462():65-70. PubMed ID: 27531412
[TBL] [Abstract][Full Text] [Related]
34. Peritonitis, peritoneal inflammation and membrane permeability: a longitudinal study of dialysate and serum MCP-1 in stable patients on peritoneal dialysis.
Malik AR; Little MA; Henriksson M; Tam FW; Brown EA
J Nephrol; 2007; 20(3):340-9. PubMed ID: 17557268
[TBL] [Abstract][Full Text] [Related]
35. Impact of a low-glucose peritoneal dialysis regimen on fibrosis and inflammation biomarkers.
Yung S; Lui SL; Ng CK; Yim A; Ma MK; Lo KY; Chow CC; Chu KH; Chak WL; Lam MF; Yung CY; Yip TP; Wong S; Tang CS; Ng FS; Chan TM
Perit Dial Int; 2015; 35(2):147-58. PubMed ID: 25904773
[TBL] [Abstract][Full Text] [Related]
36. The Association of Effluent Ca125 with Peritoneal Dialysis Technique Failure.
Barreto DL; Hoekstra T; Halbesma N; Leegte M; Boeschoten EW; Dekker FW; Krediet RT;
Perit Dial Int; 2015 Dec; 35(7):683-90. PubMed ID: 26152581
[TBL] [Abstract][Full Text] [Related]
37. Cancer antigen 125: a bulk marker for the mesothelial mass in stable peritoneal dialysis patients.
Visser CE; Brouwer-Steenbergen JJ; Betjes MG; Koomen GC; Beelen RH; Krediet RT
Nephrol Dial Transplant; 1995; 10(1):64-9. PubMed ID: 7724031
[TBL] [Abstract][Full Text] [Related]
38. Biocompatibility pattern of a bicarbonate/lactate-buffered peritoneal dialysis fluid in APD: a prospective, randomized study.
Fusshoeller A; Plail M; Grabensee B; Plum J
Nephrol Dial Transplant; 2004 Aug; 19(8):2101-6. PubMed ID: 15213322
[TBL] [Abstract][Full Text] [Related]
39. Effects of low-glucose degradation product solution on peritoneal membrane characteristics in peritoneal dialysis patients: a 3-year follow-up study.
Park JW; Kang SH; Do JY
Iran J Kidney Dis; 2014 Jan; 8(1):58-64. PubMed ID: 24413723
[TBL] [Abstract][Full Text] [Related]
40. Longitudinal follow-up of CA125 in peritoneal effluent.
Ho-dac-Pannekeet MM; Hiralall JK; Struijk DG; Krediet RT
Kidney Int; 1997 Mar; 51(3):888-93. PubMed ID: 9067926
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
